Assorted News from the Last Week: CAC2 Supporting Organization Member Day One Biopharmaceuticals announced it has entered into an exclusive licensing agreement with MabCare Therapeutics

Assorted News from the Last Week: Bristol Myers Squibb’s Augtyro (repotrectinib) has secured an accelerated approval from the FDA for the treatment of adult and

Assorted News from the Last Week: Research from the University of Birmingham could pave the way for using MRI scanning combined with machine learning to

Assorted News from the Last Week: The FDA granted accelerated approval to Eli Lilly And Co’s selpercatinib (Retevmo) for pediatric patients two years of age and

Assorted News from the Last Week: The FDA Pediatric ODAC met to “discuss perspectives on the impact of FDARA on the field of pediatric oncology,

Assorted News from the Last Week: St. Jude survivorship portal and its ability to facilitate breakthroughs in pediatric cancer survivorship research were published recently in Cancer

Assorted News from the Last Week: To understand how CNS tumors impact the AYA population, NCI-CONNECT (Comprehensive Oncology Network Evaluating Rare CNS Tumors), the Central

Assorted News from the Last Week: Brain cancer in children is notoriously hard to treat – a new mRNA cancer vaccine triggers an attack from

Assorted News from the Last Week: Congratulations to CAC2 Supporting Organization Day One Biopharmaceuticals. The FDA has granted accelerated approval to tovorafenib (Ojemda) for the

Assorted News from the Last Week: To achieve successful socioeconomic reintegration in the long term, it is crucial to implement a childhood cancer survivorship program